

Day1: October 11 (Fri)

Building	Congress Center									Congress Center				Fukuoka Sunpalace Hotel and Hall				Congress Center	Building	
Floor	3F			4F						4F	5F			2F				2F	Floor	
Venue	Room1	Room2	Room3	Room4	Room5	Room6	Room7	Room8	Room9	Room10	Room11	Room12	Room13	Room14	Room15	Room16	Room17	Poster Hall	Venue	
Room	Main Hall	411+412	413+414	409	410	401+402	403	404	405	406	502	503	501	Palace Room A	Palace Room B	Heian	Suehiro	Multipurpose Hall	Room	
8:00																				
8:10	Opening Ceremony																			
8:35		JSCNP-S1 Occupational psychopharmacology in 2019																		
8:40																				
9:00	AsCNP-S1 Maintenance treatment following remitted first episode psychosis O: Eric YH Chen C: Ichiro Kusumi	JSCNP-S2 Aims and scope for schizophrenia pharmacotherapy guidelines revised edition	JSCNP-S3 Near-future psychiatric treatment expected from state-of-the-art technology. -Liquid Biopsy, Smart Nanomachine and DNA Demethylation-	JSCNP-S4 Update 2019 of pharmacotherapy for bipolar disorders	AsCNP-S2 Developing new pharmaceutical agents for unmet medical needs in schizophrenia -From preclinical to clinical studies O: Wen-Sung Lai C: Masanari Itokawa	JSCNP-S5 From the viewpoint of each clinical department, we evaluate epilepsy from different angles ~ For skill up of the epilepsy medical treatment ~	JSCNP-S6 Practical issues on postmarketing evaluation of effectiveness and safety	JSCNP Oral Session 1	JSCNP Oral Session 2	AsCNP-S3 A cutting-edge view on how to regulate the drug dependence related behaviors O: Tomohisa Mori C: Tadashi Saigusa	AsCNP-S4 Neurobiology of endocannabinoid system in psychiatric disorders O: Hiroki Ishiguro C: Taku Yamaguchi	AsCNP-S5 Recent Advances in Autism Research from Asia O: Atsushi Sato C: Nobumasa Kato	AsCNP-S6 Novel treatment strategies based on the advanced understanding of neurobiological mechanisms in obsessive-compulsive spectrum disorder O: Hisato Matsunaga C: Tomohiro Nakao	AsCNP-S7 What can we learn from brain imaging studies of schizophrenia? From its pathophysiology to actual treatment O: Hiroyuki Uchida C: Makoto Higuchi	AsCNP-S8 Cellular and molecular signatures of psychiatric disorders in postmortem human brain O: Shinya Kasai C: Shuji Iritani	AsCNP Oral Session 1 Dementia & Neurological Disorders C: Kyung-Joon Min Kiyoyuki Kitaichi				
10:00																				
10:20																				
11:00	AsCNP-S9 Translation of Research to Clinical Practice O: Roumen Milev C: Tadafumi Kato	JSCNP-S7 Treatment strategies for severe and chronic, and treatment resistant schizophrenia, and social and medical changes based on the strategies	JSCNP-S8 Perspectives of future treatment strategies for depressive disorders with new and present antidepressants	JSCNP-S9 Pregnancy and autism spectrum disorder	JSCNP-S10 Message from MUSUBI-J study	AsCNP-S10 Novel antidepressant targets found from the central serotonergic and related systems O: Mitsuhiro Yoshioka C: Masaki Kakeyama	AsCNP-S11 The multi-dimensional approach to metabolic disturbance in schizophrenia O: Mong-Liang Lu C: Takashi Watanabe	JSCNP Oral Session 3	JSCNP Oral Session 4	JSCNP Oral Session 5	AsCNP-S12 Community Care and Global Mental Health: innovative psychiatric pharmacotherapy strategies in Asia O: Chieko Kurihara C: Kazutaka Shimoda	AsCNP-S13 The Global Collection Initiative for psychiatric genetics From genetic variation to disease mechanisms O: Yasue Horiuchi C: Hiroshi Yoneda	AsCNP-S14 Novel strategy to treat hallucinations and delusions in schizophrenia: searching for new targets in neural circuits and brain networks O: Kazuyuki Nakagome C: Akira Monji	SS1 Eisai Co., Ltd. C: Hiroyuki Uchida S: Shinichiro Nakajima Takuya Takahashi	AsCNP-S16 Stresses and psychiatric diseases ~ mechanisms, gender, treatment ~ O: Atsumi Nitta C: Hiroshi Ichinose	AsCNP Oral Session 2 Childhood & Adolescent Disorders C: Susana Shur-Fen Gau Zhong Chen				
12:00																				
12:10																				
13:00	LS1-1 H. Lundbeck A/S C: Stephen Stahl S: Stephen Stahl Bernhard T. Baune Roger McIntyre																			
13:30				LS1-4 Otsuka Pharmaceutical Co., Ltd. C: Norio Furukori S: Hiroyuki Nakanishi Akifumi Nakamura																
14:00																				
14:30																				
15:00																				
15:20	AsCNP-SL1 C: Jun Soo Kwon S: Masayo Tada																			
16:00																				
16:20																				
17:00	JSCNP-IL1 C: Reiji Yoshimura S: Andrea Fagiolini Bernhard T. Baune	SS2 Janssen Pharmaceutical K.K. C: Nakao Iwata Koichiro Watanabe S: Fuminari Misawa Naoki Hashimoto Hidehiko Takahashi	JSCNP-S11 Precision Medicine and PGx in Psychiatry	JSCNP-S12 How do you understand and overcome a placebo response?		AsCNP-S17 Clinical research of gut-microbiota-brain axis O: Chun-Hsin Chen C: Katsuji Nishimura	AsCNP-S18 Advances in animal models of drug addiction O: Soichiro Ide C: Ichiro Sora				SS4 Otsuka Pharmaceutical Co., Ltd. C: Toshikazu Saito S: Susumu Higuchi Toshikazu Saito Hisatsugu Miyata	AsCNP-S19 Future Development of Biomarker in Mental disorders O: Andi J. Tanra C: Minoru Takebayashi	AsCNP-S20 International neuroimaging big data collaborations: ENIGMA and COCORO O: Ryota Hashimoto C: Michio Suzuki	AsCNP-P1 Addiction 1 Hwei-Hsien Chen	AsCNP-P4 Bipolar Disorders 1 Po See Chen	AsCNP-P7 Depression 1 Cheng-Ta Li	AsCNP-P10 Depression 4 Hirokazu Mizoguchi	AsCNP-P13 Childhood & Adolescent Disorders 1 Atsushi Sato		
18:00																				
18:10																				
18:20																				
19:00																				
20:00																				

S: Speaker
O: Organizer
C: Chair

AsCNP Session
JSNP/JSCNP Session
JSNP Session
JSCNP Session
Sponsored Session

J: Japanese E: English
Simultaneous interpretation available

SS3
Medical Affairs Department,
SHIONOGI & CO., LTD. / Japan Medical
Office, Takeda Pharmaceutical
Company Limited
C: Takuya Saito
S: Kazuya Ono
Takuya Saito
Josep Antoni Ramos-Quiroga

AsCNP-S15
The different effects of ketamine and its enantiomers on chronic stress induced depressed animal models and clinical antidepressant and anti-suicidal effect studies in acute and maintenance therapy of patients with treatment resistant depression
O: Tung-Ping T Su
C: Hisashi Mori

LS1-13
Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd.
C: Kazuyuki Nakagome
S: Allan H. Young

LS1-15
Pfizer Japan Inc. / Sumitomo Dainippon Pharma Co., Ltd.
C: Chiaki Kawanishi
S: Nakao Iwata

AsCNP-P16
Neurological Disorders
Kazuki Nagayasu

AsCNP-P19
Pain 1
Takayuki Nakagawa

AsCNP-P22
Schizophrenia 1
Sangyeol Lee

AsCNP-P25
Schizophrenia 4
Hajime Baba

AsCNP-P28
Schizophrenia 7
Jimmy Lee